.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,884,793

« Back to Dashboard

Claims for Patent: 6,884,793

Title: Combination preparation for contraception based on natural estrogens
Abstract:The combination preparation for contraception includes from 2 to 4 first stage daily dosage portions each including an effective amount of at least one natural estrogen as sole active ingredient, from 16 to 22 second stage daily dosage portions each including an effective amount of a combination of at least one natural estrogen and at least one natural or synthetic gestogen as active ingredient; from 2 to 4 third stage daily dosage portions each including an effective amount of at least one natural estrogen as sole active ingredient; and from 2 to 4 final stage daily dosage portions containing a pharmaceutically acceptable placebo. The estrogen may be estradiol, an estradiol compound that is metabolized to estradiol when taken into the body, a conjugated equine estrogen or a phytoestrogen. The natural or synthetic gestogen can be natural progesterone or a synthetic gestogens, such as medroxyprogesterone acetate.
Inventor(s): Dittgen; Michael (Apolda, DE), Fricke; Sabine (Jena, DE), Hoffmann; Herbert (Jena, DE), Moore; Claudia (Jena, DE), Oettel; Michael (Jena, DE), Ostertag; Monika (Gottingen, DE)
Assignee: Jenapharm GmbH & Co. KG (Jena, DE)
Application Number:09/950,915
Patent Claims: 1. A combination preparation for contraception comprising a first stage consisting of two daily dosage portions, each consisting of an effective amount of estradiol valerate; a second stage consisting of a first group and a second group of daily dosage portions of a combination of said estradiol valerate and dienogest; a third stage consisting of two daily dosage portions, each consisting of an effective amount of said estradiol valerate, wherein said effective amount of said estradiol valerate in each of said two daily dosage portions in said third stage is the same, but smaller than said effective amount of said estradiol valerate in each of said two daily dosage portions in said first stage; and an additional stage consisting of two daily dosage portions, each consisting of a pharmaceutically acceptable placebo; wherein said first group of said daily dosage portions of said second stage consists of five of said daily dosage portions of said combination and wherein said second group of said daily dosage portions of said second stage consists of seventeen of said daily dosage portions of said combination; and wherein respective amounts of said estradiol valerate in each of said daily dosage portions of said second stage are equal and respective amounts of said dienogest in said daily dosage portions of said second group of said second stage are equal to 1.5 to 3 times corresponding amounts of said dienogest in said daily dosage portions of said first group of said second stage.

2. The combination preparation as defined in claim 1, wherein said effective amount of said estradiol valerate in each of said daily dosage portions during said first stage is from 3 to 4 mg/day and said corresponding amounts of said dienogest in said daily dosage portions in said first group of said second stage are minimum amounts necessary for effective contraceptive activity.

3. A combination preparation for contraception consists of a first stage consisting of three daily dosage portions, each consisting of an effective amount of estradiol valerate; a second stage consisting of a first group and a second group of daily dosage portions of a combination of said estradiol valerate and dienoest; a third stage consisting of two daily dosage portions, each consisting of an effective amount of said estradiol valerate, wherein said effective amount of said estradiol valerate in each of said two daily dosage portions in said third stage is the same, but smaller than said effective amount of said estradiol valerate in each of said two daily dosage portions in said first stage; and an additional stage consisting of three daily dosage portions, each consisting of a pharmaceutically acceptable placebo; wherein said first group of said daily dosage portions of said second stage consists of four of said daily dosage portions of said combination and wherein said second group of said daily dosage portions of said second stage consists of sixteen of said daily dosage portions of said combination; and wherein respective amounts of said estradiol valerate in each of said daily dosage portions of said second stage are equal and respective amount of said dienogest in said daily dosage portions of said second group of said second stage are equal to 1.5 to 3 times corresponding amounts of said dienogest in said daily dosage portions of said first group of said second stage.

4. The combination preparation as defined in claim 3, wherein said effective amount of said estradiol valerate in each of said daily dosage portions during said first stage is from 3 to 4 mg/day and said respective amounts of said dienogest in said daily dosage portions in said first group of said second stage is a minimum amount necessary for effective contraceptive activity.

5. The combination preparation as defined in claim 3 or 4, wherein 1 mg of said dienogest is present in each of said daily dosage portions in said first group of said second stage.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc